AfterRaise/Companies/Encoded Therapeutics

Encoded Therapeutics

$275M Series FRaised yesterdaySouth San Francisco, USABiotech & PharmaUSA
Visit website →

Why now

Where Encoded Therapeutics is today

Encoded Therapeutics announced a Series F round of $275M on 9 September 2026, led by GV and another healthcare fund.

Latest round
Series F
Amount
$275M
Announced
9 September 2026
Headquarters
South San Francisco, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
GV and another healthcare fund
Also participating
ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock
Relevant leadership
CEO Kartik Ramamoorthi

Momentum AfterRaise intelligence

AfterRaise Score

83
High momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
25/25
round size relative to the market
Funding stage
18/20
Series F
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

In their own words

What Encoded Therapeutics says it is doing

Work here? Reserve your page

Public signal Described in the funding announcement as "clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders". Source

Market expansionResearch and developmentCommercial growthManufacturing and scale

Public signal Read from the company's own description of what the funding supports.

Since the raise

What has happened since

  • 9 September 2026
    $275M Series F
    Led by GV and another healthcare fund.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • CMC and manufacturing
  • Quality systems
  • Scientific hiring
  • Licensing and BD partnerships

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

High momentum5 connected signals
  • 9 September 2026$275M Series F announced
  • 9 September 2026Stated priority: market expansion
  • 9 September 2026Stated priority: research and development
  • 9 September 2026Stated priority: commercial growth
  • 9 September 2026Stated priority: manufacturing and scale

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Encoded Therapeutics is open to

Not yet specified

Encoded Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Encoded Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Encoded Therapeutics?

Reserve your company page.

This page was created from publicly available information. When verified company accounts open, your team will be able to correct your profile, tell the market what you actually need and control how people approach you.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every company administrator is verified before access is granted.

The first 1,000 verified funded companies join the Founding 1,000 free for life and keep Founding Company status permanently.

Also moving

Other Biotech & Pharma companies

See the sector